• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia.

作者信息

Mazzaro C, Lacchin T, Moretti M, Tulissi P, Manazzone O, Colle R, Pozzato G

机构信息

First Division of Medicine, Pordenone General Hospital, Italy.

出版信息

Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S181-5.

PMID:8730503
Abstract

OBJECTIVE

As previous studies have shown a good response of mixed cryoglobulinemia (MC) to alpha-interferon (IFN) therapy, we investigated the efficacy and tolerability of two IFN regimens in a group of 36 patients affected by MC.

METHODS

The patients, diagnosed on the basis of standard clinical and laboratory criteria, were randomly divided into 2 groups: group A (18 cases) received alpha 2b-IFN 3 M.U. thrice a week for six months, while group B (18 cases) received alpha 2b-IFN thrice a week for 1 year. The patients were followed for six months after the end of therapy. Liver function tests, cryoglobulin determinations and a clinical examination were performed each month. HCV serology and HCV-RNA detection by PCR were performed before therapy and at the end of the follow-up period.

RESULTS

The two study groups were comparable in age, male/female ratio, purpura score, cryoglobulin level, mean ALT serum activity and liver histology. 32 patients (89%) were positive for anti-HCV antibodies and 29 (81%) for HCV-RNA. During therapy all patients showed a significant (p < 0.001) decrease in their cryoglobulin level as well as improvement (p < 0.05) in their purpura score. In group A, five patients (28%) showed normalized ALT, but three later relapsed. In group B seven patients (39%) responded to treatment but three relapsed after suspension of the drug. Two patients from group B developed severe side effects (hypothyroidism and depression) and therapy was discontinued after 9 and 11 months, respectively. In all the non-responders and relapsed patients, purpura, ALT, and cryoglobulins rose to pre-treatment levels within a few months. At the end of follow-up, two patients from group A (11%) and four in group B (22%) had achieved complete remission.

CONCLUSION

This study indicates that IFN is useful in MC and that viral replication can be considered the target of the therapy. Despite the absence of a statistical difference in the response rate between the two regimens (due to the low number of subjects), the one-year therapy course seemed to show a better efficacy, although associated with higher toxicity.

摘要

相似文献

1
Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia.
Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S181-5.
2
Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy.对α-干扰素治疗有反应的混合性冷球蛋白血症患者单克隆B细胞增殖的消退
Cancer. 1996 Jun 15;77(12):2604-13. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2604::AID-CNCR26>3.0.CO;2-V.
3
Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.丙型肝炎病毒阳性混合型冷球蛋白血症的干扰素治疗:影响治疗效果的病毒和宿主因素
Ital J Gastroenterol Hepatol. 1997 Aug;29(4):343-50.
4
Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia.α-干扰素治疗Ⅱ型混合性冷球蛋白血症的长期疗效
Haematologica. 1994 Jul-Aug;79(4):342-9.
5
Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).慢性丙型肝炎患者在接受6个月治疗后复发,再次接受12个月干扰素α-2b治疗的疗效更佳:一项多中心、对照、随机试验。丙型肝炎研究与治疗小组(Get.Vhc)
Hepatology. 1998 Dec;28(6):1680-6. doi: 10.1002/hep.510280631.
6
Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.持续病毒学应答患者丙型肝炎病毒相关混合性冷球蛋白血症性血管炎的复发
Arthritis Rheum. 2008 Feb;58(2):604-11. doi: 10.1002/art.23305.
7
Effectiveness of leukocyte interferon in patients affected by HCV-positive mixed cryoglobulinemia resistant to recombinant alpha-interferon.白细胞干扰素对丙型肝炎病毒阳性混合性冷球蛋白血症且对重组α干扰素耐药患者的疗效。
Clin Exp Rheumatol. 2002 Jan-Feb;20(1):27-34.
8
Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.干扰素α-2a治疗丙型肝炎病毒相关冷球蛋白血症
N Engl J Med. 1994 Mar 17;330(11):751-6. doi: 10.1056/NEJM199403173301104.
9
Interferon in the treatment of mixed cryoglobulinemia.干扰素治疗混合性冷球蛋白血症。
Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S175-80.
10
Chronic hepatitis C virus infection in renal transplant: treatment and outcome.肾移植受者的慢性丙型肝炎病毒感染:治疗与转归
Clin Transplant. 2006 Nov-Dec;20(6):677-83. doi: 10.1111/j.1399-0012.2006.00534.x.

引用本文的文献

1
Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.丙型肝炎病毒相关混合性冷球蛋白血症的治疗
Cochrane Database Syst Rev. 2018 May 7;5(5):CD011403. doi: 10.1002/14651858.CD011403.pub2.
2
Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.丙型肝炎病毒感染相关的冷球蛋白血症性和非冷球蛋白血症性周围神经病的治疗。
Cochrane Database Syst Rev. 2014 Dec 20;2014(12):CD010404. doi: 10.1002/14651858.CD010404.pub2.
3
Treatment of hepatitis C cryoglobulinemia: mission and challenges.
丙型肝炎冷球蛋白血症的治疗:任务与挑战。
Curr Treat Options Gastroenterol. 2006;9(6):497-507. doi: 10.1007/s11938-006-0006-7.
4
[Vasculitis associated with viral infections].[与病毒感染相关的血管炎]
Presse Med. 2004 Nov 6;33(19 Pt 2):1371-84. doi: 10.1016/s0755-4982(04)98936-1.
5
Symptomatic cryoglobulinemia.
Curr Treat Options Oncol. 2000 Jun;1(2):105-18. doi: 10.1007/s11864-000-0055-4.
6
Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.冷球蛋白和冷球蛋白血症。诊断与治疗考量
Clin Rev Allergy Immunol. 1998 Fall;16(3):249-64. doi: 10.1007/BF02737635.